Evidence map›Paper›PMID 36396933›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis.

Aleix Solanes, Gisela Mezquida, Joost Janssen, Silvia Amoretti, Antonio Lobo, Ana González-Pinto, Celso Arango, Eduard Vieta, Josefina Castro-Fornieles, Daniel Bergé and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 4 countries.

Aleix SolanesInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-2491-200X
Gisela MezquidaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Joost JanssenCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
Silvia AmorettiInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-6017-2734
Antonio LoboCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0002-9098-655X
Ana González-PintoCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
Celso ArangoCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0003-3382-4754
Eduard VietaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Josefina Castro-FornielesInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0003-0632-2687
Daniel BergéDepartment of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auria AlbaceteFIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.
Eloi GinéHospital de Mataró, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3130-5566
Mara ParelladaCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
Miguel BernardoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-8748-6717
PEPs group (collaborators)
Edith Pomarol-ClotetFIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain. epomarol-clotet@fidmag.org.
Joaquim RaduaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. radua@recerca.clinic.cat.
Instituto de Salud Carlos III · ESNeurosciences Institute · USUniversidad de Zaragoza · ESUniversity of the Basque Country · ESHospital Del Mar · ESUniversidad de Oviedo · ESUniversitat Autònoma de Barcelona · ESFidmag Sisters Hospitallers · ESHospital Clínic de Barcelona · ESHospital de Mataró · ESHospital Sant Joan de Déu Barcelona · ESKing's College London · GBUniversidad Complutense de Madrid · ESUniversitat de València · ES

Funding

EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health) FP7- HEALTH-2009-2.2.1-2-EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health) FP7- HEALTH-2009-2.2.1-2-241909 [Project EU-GEI]EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health) FP7- HEALTH-2009-2.2.1-3-242114 [Project OPTiMISE]EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health) FP7- HEALTH-2013-2.2.1-2-602478 [Project METSY]EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health) FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN]Euskal Herriko Unibertsitatea (University of the Basque Country) 2019 321218ELCY GIC18/107Eusko Jaurlaritza (Basque Government) 2017111104Fundación Alicia Koplowitz (Alicia Koplowitz Foundation) FAK2012, FAK2013Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) Miguel Servet Research Contracts CP14/00041 and CPII19/00009, projects PI14/00292 and PI19/00394Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI1101686
6 · The paper itself

Abstract

Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.

Identifiers

PMID36396933
PMCPMC9672064
OpenAlexW4309388820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.